Surgery Partners FCF Conversion
The FCF Conversion Rate (FCF/EBITDA) of Surgery Partners (SGRY) as of Aug 1, 2026 is -251.09 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -124.75 % — a change of 101.28% (lower).
Get this data via API
Financial Data API
FCF Conversion
-251.09 %
YoY
101.28%
Last updated:
FCF Conversion Rate (FCF/EBITDA) of Surgery Partners is 2026 -251.09 % . FCF Conversion Rate (FCF/EBITDA) of Surgery Partners was 2025 -124.75 % . It decreases by 101.28% lower compared to the previous year.
Access this data via the Eulerpool API
Surgery Partners Stock analysis
What does Surgery Partners do? Surgery Partners Inc is an American company specializing in specialized surgical services in the United States. It was founded in 1997 and is headquartered in Nashville, Tennessee. The company focuses on outpatient surgical procedures, providing a variety of medical services including eye surgery, endoscopy, ENT surgery, gynecology, orthopedic surgery, plastic surgery, and urology. Surgery Partners has over 180 surgical centers and practices in 32 states. It expanded its services through the acquisition of Symbion Healthcare in 2017, offering anesthesia services, pain management, diagnostics, and laboratory services. The company also emphasizes excellent service and has partnerships with hospitals to expand its surgical services. Surgery Partners is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Surgery Partners stock
FCF Conversion Rate (FCF/EBITDA) of Surgery Partners is -251.09 % in 2026.
Access this data via the Eulerpool API
Cash Flow — Surgery Partners
Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A
All Key Metrics — Surgery Partners
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth